A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s10637-014-0201-7
Published Online: 2014-12-23
Published Print: 2015-04
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Dittrich, Christian
Fridrik, Michael A.
Koenigsberg, Robert
Lee, Chooi
Goeldner, Rainer-Georg
Hilbert, James
Greil, Richard
Text and Data Mining valid from 2014-12-23
Version of Record valid from 2014-12-23
Article History
Received: 10 July 2014
Accepted: 12 December 2014
First Online: 23 December 2014